To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Carcinogen inducibility i… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Carcinogen inducibility in vivo and down-regulation of DMBT1 during breast carcinogenesis.

Journal article
Authors Jan Mollenhauer
Burkhard Helmke
Daniel Medina
Gaby Bergmann
Nikolaus Gassler
Hanna Müller
Stefan Lyer
Laura Diedrichs
Marcus Renner
Rainer Wittig
Stephanie Blaich
Ute Hamann
Jens Madsen
Uffe Holmskov
Floris Bikker
Antoon Ligtenberg
Anette Carlén
Jan Olsson
Herwart F Otto
Bert O'Malley
Annemarie Poustka
Published in Genes, chromosomes & cancer
Volume 39
Issue 3
Pages 185-94
ISSN 1045-2257
Publication year 2004
Published at Institute of Odontology
Pages 185-94
Language en
Links dx.doi.org/10.1002/gcc.10309
Keywords Adult, Aged, Aged, 80 and over, Agglutinins, Animals, Breast Neoplasms, genetics, metabolism, pathology, Carcinogens, metabolism, Cell Line, Tumor, DNA Mutational Analysis, methods, Down-Regulation, genetics, Female, Gene Expression Regulation, Neoplastic, drug effects, genetics, Genes, Tumor Suppressor, Humans, Lung Neoplasms, genetics, pathology, Mammary Glands, Human, drug effects, pathology, physiology, Mammary Neoplasms, Experimental, genetics, metabolism, pathology, Mice, Mice, Inbred BALB C, Middle Aged, Mutation, drug effects, genetics, Receptors, Cell Surface, biosynthesis, genetics, metabolism
Subject categories Cariology

Abstract

Deleted in malignant brain tumors 1 (DMBT1) has been proposed as a candidate tumor suppressor for brain and epithelial cancer. Initial studies suggested loss of expression rather than mutation as the predominant mode of DMBT1 inactivation. However, in situ studies in lung cancer demonstrated highly sophisticated changes of DMBT1 expression and localization, pointing to a chronological order of events. Here we report on the investigation of DMBT1 in breast cancer in order to test whether these principles might also be attributable to other tumor types. Comprehensive mutational analyses did not uncover unambiguous inactivating DMBT1 mutations in breast cancer. Expression analyses in the human and mouse mammary glands pointed to the necessity of DMBT1 induction. While age-dependent and hormonal effects could be ruled out, 9 of 10 mice showed induction of Dmbt1 expression after administration of the carcinogen 7,12-dimethybenz(alpha)anthracene prior to the onset of tumorigenesis or other histopathological changes. DMBT1 displayed significant up-regulation in human tumor-flanking tissues compared to in normal breast tissues (P < 0.05). However, the breast tumor cells displayed a switch from lumenal secretion to secretion to the extracellular matrix and a significant down-regulation compared to that in matched normal flanking tissues (P < 0.01). We concluded that loss of expression also is the predominant mode of DMBT1 inactivation in breast cancer. The dynamic behavior of DMBT1 in lung carcinoma is fully reflected in breast cancer, which suggests that this behavior might be common to tumor types arising from monolayered epithelia.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?